Ascendis Pharma A/S is a biopharmaceutical company that develops therapies for rare diseases. The company's proprietary TransCon technology platform enables the creation of new therapies that can address unmet medical needs. Ascendis Pharma's pipeline includes treatments for endocrine diseases, such as growth hormone deficiency and hypoparathyroidism, as well as rare diseases, such as achondroplasia and hemophilia. The company is headquartered in Copenhagen, Denmark and has offices in Heidelberg, Germany and Palo Alto, California.